Related Experiment Video
Updated: Jan 21, 2026

Bioengineering Human Microvascular Networks in Immunodeficient Mice
Published on: July 11, 2011
The German National Registry of Primary Immunodeficiencies (2012-2017)
Sabine M El-Helou1,2, Anika-Kerstin Biegner1, Sebastian Bode1,3
1Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Insights
The German PID-NET registry provides crucial data on primary immunodeficiencies (PID), revealing insights into prevalence, diagnosis, and treatment. This national registry aids in improving patient outcomes through timely diagnosis and enhanced care strategies.
Area of Science:
- Immunology
- Genetics
- Epidemiology
Background:
- The German PID-NET registry, established in 2009, is Germany's first national registry for primary immunodeficiencies (PID).
- It functions as part of the European Society for Immunodeficiencies (ESID) registry.
- The registry aims to collect comprehensive data on PID epidemiology, diagnosis, and treatment.
Purpose of the Study:
- To analyze epidemiological data, diagnostic delays, and treatment modalities for primary immunodeficiencies in Germany.
- To provide insights into the prevalence and characteristics of various PID types.
- To evaluate the effectiveness of diagnostic and therapeutic strategies for PID patients.
Main Methods:
- Clinical and laboratory data were collected from 2,453 patients across 36 German PID centers.
- Data was managed through an online registry and analyzed using Stata® and Excel.
- Prevalence, demographic, clinical presentation, genetic, and treatment data were systematically gathered and assessed.
Main Results:
- The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants.
- Predominantly antibody disorders were the most common PID group (57%), with infections being the most frequent presenting symptom (74%).
- Diagnostic delay showed minimal decrease overall, but significant improvements were noted for Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome, with 49% of patients receiving immunoglobulin G (IgG) substitution and 300 undergoing hematopoietic stem cell transplantation (HSCT).
Conclusions:
- The German PID-NET registry is an invaluable resource for clinicians, researchers, and policymakers.
- The registry's data supports efforts to achieve more timely diagnoses and optimize treatment for PID patients.
- Continued data collection and analysis are essential for advancing the understanding and management of primary immunodeficiencies.
Abstract:
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
More Related Videos
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
National Nursing Organizations I
National Nursing Organizations II
The AACN emphasizes a healthy work environment through six standards to achieve an optimal patient outcome. The standards are appropriate staffing, meaningful recognition, collaboration, authentic leadership, effective communication, and decision-making. In addition, AACN provides certification programs, webinars, journals, and...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Primary Active Transport
Primary and Secondary Growth in Roots and Shoots
Primary Distribution